NURS 6630 FINAL EXAM 300 ACTUAL QUESTIONS AND
CORRECT ANSWERS WITH RATIONALE ALREADY
GRADED A+ NEW!!!!!!!!!!!!!!!!!!!!!!!!
This comprehensive set of 300 multiple-choice questions covers the NURS
6630 psychopharmacology curriculum, addressing neurobiology,
neurotransmitter systems, receptor mechanisms, and pharmacologic
management of psychiatric disorders. Topics include antidepressants,
antipsychotics, mood stabilizers, stimulants, anxiolytics, and medications for
substance use disorders. Questions cover side effect profiles, drug-drug
interactions, monitoring parameters (labs, ECGs, vital signs), patient
education, and special population considerations (pregnancy, pediatrics,
elderly). Each question provides a clinical scenario with a correct answer and
detailed rationale. The content integrates pharmacokinetics,
pharmacodynamics, and clinical decision-making to prepare students for
advanced practice prescribing. No questions are repeated, ensuring
comprehensive, varied coverage.
1. A noncompliant patient states, "Why do you want me to put this poison in my
body?" Identify the best response made by the psychiatric-mental health nurse
practitioner (PMHNP).
A) "You have to take your medication to become stable."
B) "Most medications will increase the number of neurotransmitters that you
already have in the brain."
C) "Most medications used in treatment are either increasing or decreasing
neurotransmitters that your body already has."
D) "Why do you believe that your medication is poison?"
Answer: C
Rationale: The most therapeutic response educates the patient that psychotropic
medications work with the body's existing neurotransmitters, normalizing the
treatment rather than dismissing concerns .
2. Which statement about neurotransmitters and medications is true?
A) Natural neurotransmitters such as endorphins have been discovered after the
development of medications.
B) Some medications were developed after the discovery and known action of the
neurotransmitters in the brain.
,C) Neurotransmitters receive messages from most medications.
D) The neurotransmitter serotonin is directly linked to depression. Following this
discovery, the antidepressant Prozac was developed.
Answer: D
Rationale: The serotonin hypothesis of depression led to the targeted development
of SSRIs like Prozac, demonstrating how neurotransmitter discovery guides
psychopharmacology .
3. When an unstable patient asks why it is necessary to add medications to his
current regimen, the PMHNP's best response would be:
A) "In an extreme case such as yours, more than one medication is often needed."
B) "Due to the ineffectiveness of your current medication, we need to try
something else that can possibly potentiate its effects."
C) "Many psychiatric illnesses involve several dysfunctioning neurotransmitter
systems in the brain. Often, a single medication may only effect one or two of the
dysfunctioning systems. The addition of another medication can work with the
current medication in stabilizing multiple neurotransmitter systems and help to
alleviate your symptoms."
D) "I understand your concern. We can discontinue your current medication and
switch to a different one that may better manage your symptoms."
Answer: C
Rationale: This response appropriately explains the neurobiological rationale for
polypharmacy when multiple neurotransmitter systems are involved in the illness .
4. The PMHNP is evaluating a patient who is taking antipsychotics that block D2
receptors. This patient has begun to develop a common side effect of this
medication. What is this side effect?
A) Parkinson's disease
B) Tardive dyskinesia
C) Alzheimer's disease
D) Myasthenia gravis
Answer: B
Rationale: Dopamine receptor blockade, especially with long-term use, can lead to
tardive dyskinesia, a potentially irreversible movement disorder characterized by
involuntary choreoathetoid movements .
5. What is accurate about the clinical description of psychosis?
A) It is a condition that only occurs in schizophrenia.
B) It is a syndrome that can be associated with a number of psychiatric disorders.
C) It is a lifelong condition that cannot be treated.
,D) It is primarily characterized by depression.
Answer: B
Rationale: Psychosis is a syndrome that can be associated with a number of
psychiatric disorders, including schizophrenia, bipolar disorder, major depression,
and substance-induced conditions .
6. Why is the cytochrome P450 enzyme system of significance to the PMHNP?
A) The bioavailability of the medication after it passes through the stomach and
liver can be altered.
B) The system affects neurotransmitter synthesis in the brain.
C) It determines the therapeutic index of all psychotropic medications.
D) It regulates the blood-brain barrier permeability.
Answer: A
Rationale: The cytochrome P450 system, located primarily in the liver, is
responsible for metabolizing many psychotropic medications. Genetic variations in
these enzymes can significantly alter drug bioavailability and plasma
concentrations, affecting both efficacy and toxicity .
7. As it relates to G-protein linked receptors, what does the PMHNP understand
about medications that are used in practice?
A) Most medications that act on G-protein linked receptors have antagonistic traits.
B) Most medications that act on G-protein linked receptors have agonistic traits.
C) Medications that act on G-protein linked receptors are always full agonists.
D) G-protein linked receptors are not targeted by psychotropic medications.
Answer: A
Rationale: Many psychotropic medications act as antagonists at G-protein coupled
receptors, blocking rather than stimulating these slow-acting but widespread
receptors .
8. A patient with schizophrenia is given an inverse agonist that acts on the receptor
5HT and neurotransmitter serotonin. What is the rationale for prescribing a
medication such as this?
A) To promote the availability of serotonin
B) To decrease serotonin
C) To indirectly increase the amount of dopamine in the body
D) To help decrease the amount of serotonin and dopamine
Answer: D
Rationale: Inverse agonists produce the opposite effect of an agonist, effectively
decreasing the constitutive activity of the receptor. By decreasing serotonin and
dopamine activity, this can help manage symptoms of schizophrenia .
, 9. The PMHNP is caring for four patients. Which patient statement indicates that
benzodiazepines would be beneficial?
A) "I feel sad and hopeless most days."
B) "I hear voices telling me to hurt myself."
C) "I have trouble concentrating on tasks at work."
D) "I feel nervous to go outside and be in large crowds."
Answer: D
Rationale: Benzodiazepines are effective for anxiety disorders, including
agoraphobia. The patient's statement about feeling nervous in large crowds
suggests agoraphobia, which can be treated with benzodiazepines .
10. A patient is prescribed sertraline to treat panic disorder. Knowing that
sertraline can initially cause anxiety or insomnia, what should the PMHNP do?
A) Increase the dose of sertraline immediately.
B) Prescribe a short-acting benzodiazepine for 2 weeks, then discontinue.
C) Discontinue sertraline and try a different SSRI.
D) Advise the patient to take the medication only when anxiety occurs.
Answer: B
Rationale: SSRIs like sertraline can cause initial anxiety or insomnia. A short-term
prescription of a benzodiazepine can help bridge this period while the SSRI takes
effect .
11. A patient who was diagnosed with bipolar disorder without mania asks the
PMHNP why he is being prescribed a mood stabilizer. What is the appropriate
response?
A) Mood stabilizers only target mania and do not help with depression.
B) Mood stabilizers are used to prevent mania but do not treat depressive episodes.
C) Mood stabilizers can target mania and mania relapse and also reduce symptoms
of bipolar depression and relapse of bipolar depression symptoms but no drug has
been proven to target all four therapeutic actions.
D) Mood stabilizers are only effective for treating schizophrenia.
Answer: C
Rationale: This accurately explains the complex role of mood stabilizers in bipolar
spectrum disorders. Different medications may be needed to target different phases
of the illness .
12. Ms. Boeckh is a 42-year-old client who is taking an antidepressant therapy.
The PMHNP understands that this medication can have substantial food
CORRECT ANSWERS WITH RATIONALE ALREADY
GRADED A+ NEW!!!!!!!!!!!!!!!!!!!!!!!!
This comprehensive set of 300 multiple-choice questions covers the NURS
6630 psychopharmacology curriculum, addressing neurobiology,
neurotransmitter systems, receptor mechanisms, and pharmacologic
management of psychiatric disorders. Topics include antidepressants,
antipsychotics, mood stabilizers, stimulants, anxiolytics, and medications for
substance use disorders. Questions cover side effect profiles, drug-drug
interactions, monitoring parameters (labs, ECGs, vital signs), patient
education, and special population considerations (pregnancy, pediatrics,
elderly). Each question provides a clinical scenario with a correct answer and
detailed rationale. The content integrates pharmacokinetics,
pharmacodynamics, and clinical decision-making to prepare students for
advanced practice prescribing. No questions are repeated, ensuring
comprehensive, varied coverage.
1. A noncompliant patient states, "Why do you want me to put this poison in my
body?" Identify the best response made by the psychiatric-mental health nurse
practitioner (PMHNP).
A) "You have to take your medication to become stable."
B) "Most medications will increase the number of neurotransmitters that you
already have in the brain."
C) "Most medications used in treatment are either increasing or decreasing
neurotransmitters that your body already has."
D) "Why do you believe that your medication is poison?"
Answer: C
Rationale: The most therapeutic response educates the patient that psychotropic
medications work with the body's existing neurotransmitters, normalizing the
treatment rather than dismissing concerns .
2. Which statement about neurotransmitters and medications is true?
A) Natural neurotransmitters such as endorphins have been discovered after the
development of medications.
B) Some medications were developed after the discovery and known action of the
neurotransmitters in the brain.
,C) Neurotransmitters receive messages from most medications.
D) The neurotransmitter serotonin is directly linked to depression. Following this
discovery, the antidepressant Prozac was developed.
Answer: D
Rationale: The serotonin hypothesis of depression led to the targeted development
of SSRIs like Prozac, demonstrating how neurotransmitter discovery guides
psychopharmacology .
3. When an unstable patient asks why it is necessary to add medications to his
current regimen, the PMHNP's best response would be:
A) "In an extreme case such as yours, more than one medication is often needed."
B) "Due to the ineffectiveness of your current medication, we need to try
something else that can possibly potentiate its effects."
C) "Many psychiatric illnesses involve several dysfunctioning neurotransmitter
systems in the brain. Often, a single medication may only effect one or two of the
dysfunctioning systems. The addition of another medication can work with the
current medication in stabilizing multiple neurotransmitter systems and help to
alleviate your symptoms."
D) "I understand your concern. We can discontinue your current medication and
switch to a different one that may better manage your symptoms."
Answer: C
Rationale: This response appropriately explains the neurobiological rationale for
polypharmacy when multiple neurotransmitter systems are involved in the illness .
4. The PMHNP is evaluating a patient who is taking antipsychotics that block D2
receptors. This patient has begun to develop a common side effect of this
medication. What is this side effect?
A) Parkinson's disease
B) Tardive dyskinesia
C) Alzheimer's disease
D) Myasthenia gravis
Answer: B
Rationale: Dopamine receptor blockade, especially with long-term use, can lead to
tardive dyskinesia, a potentially irreversible movement disorder characterized by
involuntary choreoathetoid movements .
5. What is accurate about the clinical description of psychosis?
A) It is a condition that only occurs in schizophrenia.
B) It is a syndrome that can be associated with a number of psychiatric disorders.
C) It is a lifelong condition that cannot be treated.
,D) It is primarily characterized by depression.
Answer: B
Rationale: Psychosis is a syndrome that can be associated with a number of
psychiatric disorders, including schizophrenia, bipolar disorder, major depression,
and substance-induced conditions .
6. Why is the cytochrome P450 enzyme system of significance to the PMHNP?
A) The bioavailability of the medication after it passes through the stomach and
liver can be altered.
B) The system affects neurotransmitter synthesis in the brain.
C) It determines the therapeutic index of all psychotropic medications.
D) It regulates the blood-brain barrier permeability.
Answer: A
Rationale: The cytochrome P450 system, located primarily in the liver, is
responsible for metabolizing many psychotropic medications. Genetic variations in
these enzymes can significantly alter drug bioavailability and plasma
concentrations, affecting both efficacy and toxicity .
7. As it relates to G-protein linked receptors, what does the PMHNP understand
about medications that are used in practice?
A) Most medications that act on G-protein linked receptors have antagonistic traits.
B) Most medications that act on G-protein linked receptors have agonistic traits.
C) Medications that act on G-protein linked receptors are always full agonists.
D) G-protein linked receptors are not targeted by psychotropic medications.
Answer: A
Rationale: Many psychotropic medications act as antagonists at G-protein coupled
receptors, blocking rather than stimulating these slow-acting but widespread
receptors .
8. A patient with schizophrenia is given an inverse agonist that acts on the receptor
5HT and neurotransmitter serotonin. What is the rationale for prescribing a
medication such as this?
A) To promote the availability of serotonin
B) To decrease serotonin
C) To indirectly increase the amount of dopamine in the body
D) To help decrease the amount of serotonin and dopamine
Answer: D
Rationale: Inverse agonists produce the opposite effect of an agonist, effectively
decreasing the constitutive activity of the receptor. By decreasing serotonin and
dopamine activity, this can help manage symptoms of schizophrenia .
, 9. The PMHNP is caring for four patients. Which patient statement indicates that
benzodiazepines would be beneficial?
A) "I feel sad and hopeless most days."
B) "I hear voices telling me to hurt myself."
C) "I have trouble concentrating on tasks at work."
D) "I feel nervous to go outside and be in large crowds."
Answer: D
Rationale: Benzodiazepines are effective for anxiety disorders, including
agoraphobia. The patient's statement about feeling nervous in large crowds
suggests agoraphobia, which can be treated with benzodiazepines .
10. A patient is prescribed sertraline to treat panic disorder. Knowing that
sertraline can initially cause anxiety or insomnia, what should the PMHNP do?
A) Increase the dose of sertraline immediately.
B) Prescribe a short-acting benzodiazepine for 2 weeks, then discontinue.
C) Discontinue sertraline and try a different SSRI.
D) Advise the patient to take the medication only when anxiety occurs.
Answer: B
Rationale: SSRIs like sertraline can cause initial anxiety or insomnia. A short-term
prescription of a benzodiazepine can help bridge this period while the SSRI takes
effect .
11. A patient who was diagnosed with bipolar disorder without mania asks the
PMHNP why he is being prescribed a mood stabilizer. What is the appropriate
response?
A) Mood stabilizers only target mania and do not help with depression.
B) Mood stabilizers are used to prevent mania but do not treat depressive episodes.
C) Mood stabilizers can target mania and mania relapse and also reduce symptoms
of bipolar depression and relapse of bipolar depression symptoms but no drug has
been proven to target all four therapeutic actions.
D) Mood stabilizers are only effective for treating schizophrenia.
Answer: C
Rationale: This accurately explains the complex role of mood stabilizers in bipolar
spectrum disorders. Different medications may be needed to target different phases
of the illness .
12. Ms. Boeckh is a 42-year-old client who is taking an antidepressant therapy.
The PMHNP understands that this medication can have substantial food
